ClinicalTrials.gg

Program

IBI3031

A development code.

Its studies are mostly in Graves Ophthalmopathy, led by Innovent Biologics.

Furthest: phase 1, since May 19, 20261 company-led study, 1 open or runningNext primary completion: Jun 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics11 open or runningphase 1since May 19, 2026May 19, 2026Jun 15, 2027phase 1 · NCT07622368

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2026First study: phase 1 study in Graves OphthalmopathyFirst studyNCT07622368 · 66 planned · China

Ahead

  1. Jun 15, 2027Primary completion: phase 1 study in Graves OphthalmopathyNCT07622368

TargetBeta

IGF1R →TSHR →read by rule
“IBI3031 is an IGF-1R(Insulin-like growth factor 1 receptor)/TSHR(Thyroid-stimulating hormone receptor) bispecific antibody with potential synergistic therapeutic efficacy in TED and modulatory effects on thyroid function.”study text, by rule · the study

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07622368Graves Ophthalmopathy · China1RecruitingJun 15, 202766

How it is read

Names in the registry

  • “IBI3031”, 1 entry

Codes read as this program: IBI3031.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.